Abstract

Background: Several studies have showed that the prognosis and the incidence of Kaposi disease had been improved in many countries where HAART was accessible and provided. In Cote d’Ivoire, an improvement of ART accessibility has occurred since 2006, but, few studies have been conducted for measuring potential changes in the epidemiology and the prognosis of the Kaposi disease. The dermatology department of the Teaching Hospital of Treichville, as a reference center for this disease could reflect the changes of interest. This study was first aiming at describing the clinical, therapeutic and progressive aspects of Kaposi disease in HIV-positive patients admitted to the service, then measuring the impact of the improved HAART accessibility. Material and methods: It was a retrospective, describtive and cross-sectionnal study, based on HIV-positive patients medical records from those hospitalized for Kaposi Disease from 1995 to 2010, in the dermatology department of the teaching hospital of Treichville. Results: 96 Medical records from patients were included, which frequency was 6.4 cases/year in hospitalization. The sex-ratio was 1.97 and the mean age was 40, 2 years. The skin lesions were ulcerative and budding in 36.2% of cases; mucous lesions were found in 14.2% and visceral lesions were found in 51% of cases.83 patients were under chemotherapy (86.4%) and 32 were under HAART (33.3%). 5 were not treated for Kaposi disease. The global mortality rate was 39.6%. The frequency of hospital patients decreased from 6.4 cases /year to 1.5 cases /year by 2009.The visceral lesions were frequents (51%) from 1995 to 2009 afterward they were absents. The chemotherapy was the first choice treatment. Interferon was used in 1995 and in 1996 and was abandoned because of the high cost. 20 out of 32 patients were under HAART by 2006. From 1995 to 2008, almost half the patients were dying (40.8%), but, since 2009, no death related to Kaposi disease was observed. Though the global mortality rate was 39.6%, it was almost twice higher among patients without ART (46.9%) as compared to those under HAART (25%). The improvement of the HAART accessibility which occurred in 2006, had impacted the hospitalization frequency, the disease progressive course; clinical and treatment aspects and the mortality rate of Kaposi disease after 3 years.

Highlights

  • Several studies have showed that the prognosis and the incidence of Kaposi disease had been improved in many countries where HAART was accessible and provided

  • Kaposi disease of HIV positive patients has its clinically characterized by its visceral involvements especially the pulmonary location, that can be life-threatening

  • We have conducted a descriptive, cross-sectionnal study, using the medical records of HIV positive patients admitted for Kaposi disease, from 1995 to 2010 to the dermatology service of the University Hospital of Treichville, in Abidjan

Read more

Summary

Introduction

Several studies have showed that the prognosis and the incidence of Kaposi disease had been improved in many countries where HAART was accessible and provided. In Côte d’Ivoire, an improvement of ART accessibility has occurred since 2006, but, few studies have been conducted for measuring potential changes in the epidemiology and the prognosis of the Kaposi disease. The dermatology department of the Teaching Hospital of Treichville, as a reference center for this disease could reflect the changes of interest. Few studies have been conducted to capture potential changes in the epidemiology and the prognosis of the Kaposi disease in the country. The Department of Dermatology and Venereology of the University Hospital of Treichville, as a reference center for this disease, could reflect the answer to these questions. This study was first aiming at 1) describing the clinical, therapeutic and progressive aspects of Kaposi disease in HIV positive patients admitted to the service, 2) measuring the impact of the improved access to HAART.

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.